LGND
Ligand Pharmaceuticals Incorporated · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -20.0% ·
share flow -9.5% ·
net new positions -20.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | -1 | 3.32K | $979,400 | n/a | −2 |
| Q2 2026 | 109 | +8 | 14.85M | $4.69B | +14 | −8 |
| Q1 2026 | 106 | -5 | 14.62M | $2.92B | +4 | −9 |
| Q4 2025 | 110 | 0 | 15.70M | $2.97B | +1 | −1 |
| Q3 2025 | 17 | +2 | 7.48M | $1.32B | +3 | −2 |
| Q2 2025 | 13 | 0 | 6.47M | $735.39M | +3 | −3 |
| Q1 2025 | 10 | +3 | 1.36M | $143.17M | +3 | n/a |
| Q4 2024 | 7 | -2 | 1.36M | $145.21M | n/a | −2 |
| Q3 2024 | 8 | -2 | 597.13K | $59.78M | n/a | −2 |
| Q2 2024 | 10 | n/a | 659.66K | $55.58M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 428.27K | +5.5% | $42.87M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 2 | Fisher Asset Management ✦ | 59.57K | +12.4% | $5.96M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Norges Bank ✦ (passive) | 57.05K | -24.1% | $5.71M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 23.81K | -48.0% | $2.38M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 13.74K | +1.1% | $1.38M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 6 | Wellington Management ✦ | 8.69K | -39.7% | $869,583 | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 7 | Two Sigma Investments ✦ | 3.00K | 0.0% | $300,270 | 0.0% | Held | 2 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 3.00K | -83.5% | $300,270 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| D. E. Shaw & Co. | $2.17M | was 0.0% |
| AQR Capital Management | $407,313 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 353 holders, 20.71M shares, $4.06B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 235 sh · $72,190
Officer · 404 sh · $123,698
Officer · 17 sh · $5,232
Officer · 1.53K sh · $467,431
Officer · 1.98K sh · $599,804
Officer · 833 sh · $251,991
Director · 1.20K sh · $342,000
Officer · 385 sh · $110,697
Officer · 300 sh · $85,196
Officer · 1.80K sh · $513,301
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology